LONDON (Reuters) – Doctors should use cholesterol-lowering statin drugs much more widely to prevent heart attacks and strokes, according to Britain’s healthcare cost-effectiveness watchdog.
In a major revision to 2008 guidelines, the National Institute for Health and Care Excellence (NICE) recommends the threshold for starting on statins should be halved from a 20 percent risk of developing cardiovascular disease over 10 years to a 10 percent risk.
Deal for #L’Oreal to buy 8% of its shares from #Nestle won’t require disposal of #Sanofi shares held by L’Oreal, French cosmetics group says
LONDON, Feb 7 (Reuters) – Pharmaceuticals group Shire
has halted development of its top-selling hyperactivity
drug Vyvanse as a treatment for depression after it failed to
treat patients successfully in two late-stage clinical trials.
The news sent the drugmaker’s high-flying shares down by
about 2 percent to 30.80 pounds by 0830 GMT, though they remain
within a whisker of this week’s record high of 31.53 pounds,
reflecting investor confidence in Shire’s underlying growth.
LONDON, Feb 6 (Reuters) – AstraZeneca is moving an
experimental Alzheimer’s drug into late-stage development,
taking on U.S. rival Merck & Co which announced plans to
start similar final-stage research in December.
Britain’s second-biggest drugmaker revealed its plan to move
AZD3293 into the last phase of testing needed for registration
as it announced full-year results on Thursday.
MUMBAI/LONDON (Reuters) – Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.
An Indian government committee is reviewing patented drugs of foreign firms to see if so-called compulsory licences, which in effect break exclusivity rights, can be issued for some of them to bring down costs, two senior government officials told Reuters.